{"analyses":[{"ciLowerLimit":"0.531","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.825","groupDescription":"All analyses based on final DBL were descriptive only with p-values reported as nominal.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.662","statisticalMethod":"Stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.9","upperLimit":"23.9","value":"21.1"},{"groupId":"OG001","lowerLimit":"10.6","upperLimit":"16.1","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Part 2 participants only","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 68.4 months","title":"Part 2: OS","type":"PRIMARY","unitOfMeasure":"months"}